Given the heterogeneity of glucose and lipid metabolism in both GDM and prediabetes, accurately characterizing the degree of insulin secretion and insulin resistance defects in patients would allow for better treatment of GDM-related outcomes. The gene discussed is INS; the disease is prediabetes syndrome.